Podcast: Paul Rennie, CEO of Paradigm Biopharma

About the author:

Scott Power
Author name:
By Scott Power
Job title:
Senior Analyst
Date posted:
11 January 2018, 10:58 AM
Sectors Covered:
Healthcare, Life Science and Technology

In this podcast, I speak with Paul Rennie, Chief Executive Officer of Paradigm Biopharma. Paul describes company operations, clinical trials and the special access scheme that's currently underway. 

"In addition to the two clinical trials, the drug pentosan polysulphate sodium (PPS) is registered in other countries. As a result of that, the Therapeutic Goods Administration (TGA) allows doctors to access the drug through a scheme called the Special Access Scheme Category B. This means that doctors can apply to the TGA when they believe that the patient could benefit from the use of PPS."

Listen to the podcast:

More information

Morgans clients can access our detailed research on all companies we cover in the Healthcare sector. If you are interested in finding out more, please contact your nearest Morgans office.

Disclaimer(s): Analyst may owns shares in some or all stocks mentioned.

The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.

  • Print this page
  • Copy Link